receptor.
. This heterogeneity of hGH concentrations measured by different immunoassay kits has been attributed to the use of different reference preparations (4), to the heterogeneity of different forms of GH in circulation (5,6), the epitope specificity of the antibodies employed (7), and differences in standard matrix (8). The diagnostic procedures in the evaluation of suspected GH deficiency in childhood (9,lO) and recently also in adult patients (11) involve GH measurement after provocative tests. The results obtained by these measurements have profound effects on establishment of the diagnosis and represent the key criteria for reimbursement of the GH replacement therapy costs. Although recommendations exist concerning the provocative testing procedures for the diagnosis of GH deficiency, and cut-off levels have been proposed below which the peak GH levels after provocative tests should be, no consensus has been achieved or proposed for the biochemical procedure of GH measurement itself. The essential information requested by blood sampling for GH determination is the amount of biologically active, functional GH in the circulation at the time of blood sampling. The answer commonly provided by the analytical results, in contrast, represents a quantitation of immunoreactive GH molecular forms in the sample, to which variants, fragments, and aggregates of GH (6) contribute to different extents depending on the epitope specificity of the antibodies employed in the assay (1, 12) .
hGH has been shown to induce dimerization of its receptor as the initial step of signal transduction in target cells (13), which leads to phosphorylation of the intracellular domain of the hGH receptor and receptor-associated proteins (14). This process initiates the signal transduction cascade involving JAK2 kinase and STAT (Signal Transducence  and Activation of Transcription) proteins (15, 16) . The x-ray crystallography structure of a complex formed by one molecule of GH and two GH receptor ecto domains was resolved (171, and the epitopes of the hGH molecule interacting with either receptor molecule have been characterized. The GH molecule sequentially binds to a first receptor molecule with a large contact surface area involving a total of 31 amino acid side-chains (18) of the C-terminal part of the fourth helix bundle, parts of the random coil sequence between helix 1 and helix 2, and parts of helix 1 (13, 19) . Consecutively, this 1:l complex associates a second receptor molecule via binding site 2 of hGH, which represents a much smaller surface area on the N-terminal random coil sequence, the beginning of helix 1 and C-terminal parts of helix 3 of the hGH molecule (13).
We have sought to identify monoclonal antibodies (mAbs) specific for both binding domains on the hGH molecule that interact with the receptor molecules and attempted to design an immunoassay procedure more closely reflecting in its results the biologically active proportion of GH in a given serum sample (7). As the epitope recognized by mAbs generally spans over 3-10 amino acid residues (201, no single mAb could be identified representatively binding to the 31 amino acid side-chains involved in interaction on binding site 1 with the receptor (18).
This article describes our approach to design an immunofunctional assay (IFA) for hGH in which only those molecular forms of hGH in the sample to be analyzed translate into an assay signal that is also capable of inducing a receptor dimerization and thereby initiating the signal transduction process on target cells. The IFA is based on the interaction of GH with an immobilized mAb specific for binding site 2 of the hormone and with biotin-labeled recombinant hGH (rhGH)-binding protein (hGHBP), which represents the fulllength GH receptor ecto domain. proposed by Cunningham et nl. (13); the circle shows the deduced binding epitope of mAb 7Bll.
Materials and Methods Reagents

Functional relevance of mAb 7Bll binding to hGH
Twenty-two-kilodalton hGH immobilized via mAb lOA binding an epitope distant from both receptor-binding sites of the hGH molecule was loaded with biotin-labeled rh-GHBP, and the displacing potencies of increasing concentrations of mAb 7811 and mAb 8Bll were investigated as described above. mAb 8811 bound within binding site 1 of the hGH molecule. The experiment shows that mAb 7Bll maximally displaced 50% of the labeled binding protein molecules, in keeping with blocking of binding site 2. In contrast, increasing concentrations of mAb 8Bll hindered the association of hGH with rhGHBP on binding site 1 and, therefore, consecutively also on binding site 2 and displaced all labeled rhGHBP. Fifty percent displacement was achieved at 30 ng mAb 8811 /well. Results are shown in Fig. 3 . Sensitivity and assay range Figure 4 shows two hGH IFA standard curves obtained by use of pituitary-derived hGH and rhGH (NIBSC 88/624); the mean +-1 SD of three independent hGH-IFA standard curves ran in duplicate are displayed. The rhGH preparation was more potent than the pituitary-derived hGH. The lower detection limit (sensitivity), as defined by the mean ? 3 SD of a 20-fold zero standard determination, was 0.05 pg/L. The standard curve was linear in a double logarithmic plot of signal over hGH doses up to a concentration of at least 50 l-%/L. 
Assay reproducibility
Within-assay coefficients of variation were determined for three sera in an l&fold analysis. At concentrations of 0.43, 5.3, and 19.2 pg/L, the within-assay coefficients of variation were 8.5%, 7.3%, and 6.1%, respectively. Between-assay reproducibility was analyzed by measurements of the same sera in eight independent assays. The respective betweenassay coefficients of variation were 12.8%, 9.4%, and 7.9%.
Znterference of endogenous hGHBP with the hGH IFA Fixed concentrations of hGH were preincubated with increasing concentrations of rhGHBP. One microgram per L hGH, corresponding to a 45.5 pmol/L concentration, showed the highest susceptibility to interference from endogenous hGHBP. At 2000 pmol/L rhGHBP, the detected concentration of hGH was 97%; at 5000 pmol/L rhGHBP, it was reduced to 56%. Higher concentrations of hGH were less prone to interference. The results of this experiment are shown in Fig. 5 . As the physiological concentration of hGHBP in serum samples is approximately 1000 pmol/L (range, 56-1187 pmol/L) (27), no significant interference was expected from endogenous hGHBP concentrations in hGH results obtained by the IFA following this protocol.
Linearity and recovery
The linearity of the hGH IFA was evaluated by dilution of serum samples in sheep serum. The results obtained from the IFA were compared to the calculated results. The measured results were within a range of 89-104% of those expected, with a mean of 97.5%. The detailed linearity results are shown in Table 2 .
Recovery was evaluated by mixing equal volumes of different sera with rhGH calibrators in sheep serum and assaying these as unknowns. The measured results were within 94.7% and 111.7% of those expected, with a mean 2 SD of 100.5 2 7.1%.
Specificity of the assay hPL and 20-kDa hGH, as well as hGH dimers were serially diluted in sheep serum and measured as unknowns in the hGH IFA. Cross-reaction of hPL in the hGH IFA was below 0.001%; 10 mg/L hPL gave no detectable signal. Twentykilodalton rhGH showed a relative potency of 0.16% compared to 22-kDa hGH; the dose-response curve was linear in the detectable range between 200-1000 pg/L. Dimers had a relative potency of 111.6%. These specificity data indicate that hPL, which may circulate in extremely high levels during pregnancy, will not interfere in the assay. We decided to compare the hGH-IFA to the polyclonal competitive RIA because the latter method is the most widely applied technique for hGH measurement worldwide and is assumed to yield comparable results between different laboratories. When comparing the results from 128 serum samples from different patients between the hGH IFA and the RIA, both using rhGH as the standard, the IFA yielded, on the average, 73.2% of the concentration determined by the RIA (Fig. 6A ). This result indicates that serum samples, on the average, contain 27% of molecular forms of hGH that are recognized by RIA, but do not express both binding sites 1 and 2 as measured in the IFA. When replacing the standard used in the RIA by pituitary-derived hGH, as most commonly used throughout, and comparing the results to those from the IFA calibrated again by rhGH, the IFA detects, on the average, 30% of the RIA result (Fig. 6B) . The major contribution to this heterology, as deduced from comparing Fig.  6 , A and B, is contributed by the heterology of standards; the remainder is determined by the existence of bioinactive hGH forms. The scatter of individual samples around the regression line in the latter re 9 ression analysis is reflected by a correlation coefficient of r = 0.869, indicating that the degree of bioinactive hGH forms in circulation differs between individuals. On an individual basis, the degree of immunofunctionally active hGH forms in serum samples, as calculated by comparison of IFA and RIA results from assays both using rhGH as calibrators (Fig. 6A) , varied between 52-93%.
Comparison of hGH IFA with Nb2 cell bioassay
Eighteen sera collected for GH determination in the Section of Pediatric Endocrinology at the Universitats-Kinderklinik (Tubingen, Germany) were selected to cover a range between 1.0-25.8 pg/L by RIA. These sera were analyzed additionally in the Nb2 cell assay and by IFA. The correlation between RIA and Nb2 cell assay, both calibrated against pituitary-derived hGH IRP 80/505, was r2 = 0.84, with a regression line equation of ycNbZ) = 0.39 + 0.89x(,,,,. IFA results, derived from calibration with recombinant International Reference Preparation 88/624, compared to RIA with r2 = 0.88 and a regression line of yeFA) = 0.04 + 0.54x0,,,. The agreement between Nb2 cell assay and the hGH IFA, as shown in Fig. 7 , was higher than that of either of the methods compared to RIA, with r2 = 0.97, ycNb2) = -0.04 + 0.58x0,,,. JCE & M . 1996 Volt31 . do not result in significant interference with the hGH results derived from the IFA method. By comparison of results from 128 sera measured in both a competitive polyclonal RIA using the same rhGH reference preparation 88/624 and the IFA, it can be concluded that, on the average, 27% of molecular forms in circulation give rise to a signal in the RIA, but not in the IFA. From the design of the IFA, we conclude that these 27% of hGH forms in circulation do not possess both binding sites for the receptor and, therefore, would not be able to initiate a signal transduction process at target cells, which is known to require receptor dimerization. When comparing the results obtained by use of the IFA and rhGH as the calibrator to those obtained from polyclonal RIA calibrated by use of pituitary hGH, the IFA results were, on the average, only 30% of those from the RIA. The major contribution to this discrepancy, however, is from the different potencies of the calibrators. Direct comparison of RIA results obtained by use of pituitary-derived VS. recombinant calibrator shows a decline in hGH levels to less than 50%. The remainder of the discrepancy between IFA and RIA results accounts for molecular forms not recognized in the IFA, but giving a signal in the RIA.
One possible limitation of the method is its relative overestimation of hGH dimers. After binding to the immobilized mAb 7811, some of the hGH dimer molecules appear to be capable of binding two labeled hGH receptor ecto domains (hGHBP). An interesting observation was that recombinant 20-kDa hGH showed a dose-response curve parallel to that of 22-kDa hGH, but with a potency of only 0.16% relative to that of 22-kDa hGH. The existing body of literature is controversial as to whether 20-kDa hGH can activate the GH receptor. hPL, the concentration of which in late pregnancy is known to exceed that of GH by a factor of 1000, shares 85% amino acid homology with hGH. At concentrations up to 10 mg/L, hPL does not result in a measurable signal in the hGH IFA.
The use of biotin as a primary probe in the IFA described here allows for versatile end-point determination; the streptavidin-europium conjugate used by us can easily be replaced by a streptavidin-enzyme conjugate for calorimetric end-point determination or any other label attached to streptavidin for which a laboratory is equipped with the respective measurement device. This, in principle, allows for application of the IFA in any endocrine laboratory.
Theoretically, bioassays, although more cumbersome in performance, could provide reliable estimates of biologically active GH levels in serum. The results of hGH determinations by bioassays, however, have to be interpreted with caution, bearing in mind that in these systems the interaction of hGH with receptors of other species, mostly rat GH receptors (28) or rat PRL receptors (29), is monitored. The employment of hGH receptors as expressed on IM9 cells in a competitive binding assay is limited by a lower detection limit of -2 pg/L (30) due to the rather low affinity of the hGH receptor for its specific ligand, which is on the order of 1 nmol/L. Liver membrane RRAs lack specificity for hGH (31). The Nb2 cell assay (26), which employs rat lymphoma cells expressing a short form of the rat PRL receptor with a higher affinity for hGH than the hGH receptor with a K, of 1 x 10" L/mol appears to be the sole bioassay for hGH that can be performed with tolerable effort in large scale sample series and provides sufficient sensitivity to measure GH levels in the relevant clinical range down to 0.1 kg/L. In Fig. 7 , we show very good agreement between the results of the Nb2 cell assay and the hGH IFA in 18 sera. Whether the agreement between the two methods is as high in all instances remains to be investigated by larger series of samples. Potential discrepant results from the Nb2 cell assay and the hGH IFA could be explained by the fact that the Nb2 cell assay studies the interaction of GH with a heterologous receptor and requires blocking of endogenous PRL by the addition of a neutralizing antibody. Independently of these theoretical concerns, the performance and handling of the hGH IFA are substantially easier than those of the Nb2 cell assay because living cells are not used, even though an elegant modified version of the Nb2 cell assay has recently been described in this journal by Dattani et al. (32) .
The high degree of heterogeneity in results of hGH measurements performed by different immunoassays
(1) poses a major problem in the standardization of cut-off levels for GH provocative testing. Until now, the highest degree of comparability between results from different laboratories was achieved by application of polyclonal competitive immunoassays. As a consequence of the variations in specificity of the antibodies employed, results differ even between these assays.
As the diagnosis of GH deficiency results in GH replacement therapy, which implies the need for daily SC injections for the patient and substantial cost for the health care system, transparent and standardized diagnostic criteria have to be postulated for the establishment of this diagnosis. Determination of GH levels in provocative tests presently is required for confirmation of the diagnosis and in many countries also for the reimbursement of therapy costs. We, therefore, consider crucial the standardization of the assay procedure and reference preparation used.
For the purpose of harmonization of immunoassay measurements of hGH levels, a consensus has to be achieved with respect to the reference preparation of hGH used for calibration of these methods. Recombinant 22-kDa hGH has recently become available as an international reference preparation and represents a homogeneous, well defined hGH standard. For elimination of heterogeneity in assay results that are attributed to differences in epitope specificities, we propose the IFA method as a possible gold standard for hGH quantitation.
We are currently using the IFA to establish empirical cutoff levels in hGH provocative testing by insulin tolerance test and arginine infusion. Additionally, we intend to address the question of changes in the ratio between immunoassayable and immunofunctionally active forms of hGH in different dynamic tests.
